APVO Stock Summary and Trading Ideas (Aptevo Therapeutics | NASDAQ:APVO)

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Aptevo Therapeutics trades on the NASDAQ stock market under the symbol APVO.

As of December 19, 2025, APVO stock price climbed to $1.07 with 1,024,959 million shares trading.

APVO has a beta of -0.41, meaning it tends to be less sensitive to market movements. APVO has a correlation of 0.00 to the broad based SPY ETF.

APVO has a market cap of $18.03 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APVO traded as high as $84,004.89 and as low as $1.00.

APVO has underperformed the market in the last year with a price return of -98.8% while the SPY ETF gained +18.1%. APVO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.2% and -20.7%, respectively, while the SPY returned +2.8% and -0.5%, respectively.

APVO support price is $.98 and resistance is $1.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APVO shares will trade within this expected range on the day.